SCHEMBL6922247

SCHEMBL6922247

COCC1CCc2nc3cc(-c4cccc(F)c4)ccc3c(=O)n2CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.40
RAB9A P51151 6/20 0.38
NPC1 O15118 4/20 0.38
BRD4 O60885 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
APOBEC3A P31941 1/20 0.37
APOBEC3G Q9HC16 1/20 0.37
HTR4 Q13639 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
BCHE P06276 1/20 0.36
CFTR P13569 1/20 0.36
ALOX15 P16050 1/20 0.36
ACHE P22303 1/20 0.36
HKDC1 Q2TB90 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059075 0.92 GRM2 (0.37) KMT2ARAB9ANPC1BRD4L3MBTL1
SCHEMBL6921833 0.87 RAB9A (0.42) RAB9ANPC1L3MBTL1CYP1A2CYP3A4
SCHEMBL12059151 0.87 RAB9A (0.38) RAB9ANPC1L3MBTL1CYP1A2CYP3A4
SCHEMBL6922469 0.86 L3MBTL1 (0.40) KMT2ARAB9ANPC1L3MBTL1KDM4E
SCHEMBL12059776 0.85 RAB9A (0.40) RAB9ANPC1L3MBTL1CYP1A2CYP3A4
SCHEMBL6921830 0.84 RAB9A (0.41) KMT2ARAB9ANPC1L3MBTL1CYP1A2
SCHEMBL6920741 0.84 RAB9A (0.41) KMT2ARAB9ANPC1L3MBTL1CYP1A2
SCHEMBL6920796 0.82 SSTR2 (0.45) KMT2ARAB9ANPC1L3MBTL1CYP1A2
SCHEMBL6920820 0.82 RAB9A (0.43) KMT2ARAB9ANPC1L3MBTL1CYP1A2
SCHEMBL6923633 0.82 RAB9A (0.42) KMT2ARAB9ANPC1L3MBTL1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 KMT2A 944/4885RAB9A 1387/4885NPC1 811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.